CAJ | 학술논문

尽管在全球范围内提倡的急性髓系白血病(AML)规范化分层治疗有效地改善了该病的疗效和预后,但由于白血病细胞的个体生物学差异,大多数患者最终会出现治疗失败、疾病复发,甚至死亡；另有部分初诊患者对现有的联合化疗天然耐药,预后极差.文章概括了复发难治性AML的概念,描述了复发难治的发病机制,并从治疗原则、临床用药、造血干细胞移植(HSCT)三个方面进行了阐述.对复发难治AML的诊疗进展进行回顾,将有助于掌握疾病特点并指导临床治疗.
진관재전구범위내제창적급성수계백혈병(AML)규범화분층치료유효지개선료해병적료효화예후,단유우백혈병세포적개체생물학차이,대다수환자최종회출현치료실패、질병복발,심지사망；령유부분초진환자대현유적연합화료천연내약,예후겁차.문장개괄료복발난치성AML적개념,묘술료복발난치적발병궤제,병종치료원칙、림상용약、조혈간세포이식(HSCT)삼개방면진행료천술.대복발난치AML적진료진전진행회고,장유조우장악질병특점병지도림상치료.
Although globally recommended standardized stratification treatment of acute myeloid leukemia (AML) effectively improves its therapeutic effects and prognosis,due to unknown personalized differences of tumorous biology,most of the patients eventually develop to therapy failure,relapse,and even death.Additionally,a number of patients are naturally resistant to current used combined chemotherapy and with extremely poor prognosis,This review presents definitions of refractory and relapsed AML,then describes their pathogenetic mechanism and lastly summarizes three aspects of therapeutic principle,clinical drugs and hematopoietic stem cell transplantation (HSCT).To review advances in relapsed and refractory AML diagnosis and treatment will be helpful to master disease characteristics and to guide clinical treatment.